Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Home
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • About
  • Contact
  • Register
  • Login

Issues

Präklinische und klinische Forschungsprojekte zu Apremilast

Präklinische und klinische Forschungsprojekte zu Apremilast

Thaçi, M. Augustin, A. Böhner, V. Ellenrieder, S. Finzel, K. Loser, T. Luger, R. Mößner, A. Pinter, J. Rech, K. Scharfetter-Kochanek, P. Sewerin, C. Sunderkötter, T. Witte   Einleitung Der...

Lanadelumab (TAKHZYRO®)

Lanadelumab (TAKHZYRO®)

Das hereditäre Angioödem (HAE) ist eine genetische Erkrankung, bei der die Betroffenen unter wiederholten Ödem-Attacken (Schwellungen) in verschiedenen Körperregionen leiden.1,2 Hinzu kommt die...

Addition of ribociclib to firstline letrozole improves outcomes and maintains quality of life in postmenopausal women with HR+, HER2– advanced breast cancer, regardless of visceral metastases or dose intensity: Subgroup analyses from the MONALEESA-2 trial

Addition of ribociclib to firstline letrozole improves outcomes and maintains quality of life in postmenopausal women with HR+, HER2– advanced breast cancer, regardless of visceral metastases or dose intensity: Subgroup analyses from the MONALEESA-2 trial

Standard initial treatment for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer is endocrine therapy (ET).1 Current guidelines support the use of ET as monotherapy or...

Dupilumab bei atopischer Dermatitis

Dupilumab bei atopischer Dermatitis

50. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG) In klinischen Studien profitierten Patienten mit einer mittelschweren bis schweren atopischen Dermatitis von einer Therapie mit...

The Latest Guideline-Recommended Integrase Inhibitor for the Treatment of HIV Infection – Expert Opinions

The Latest Guideline-Recommended Integrase Inhibitor for the Treatment of HIV Infection – Expert Opinions

Over the past decade, treatments for human immunodeficiency virus (HIV) infection have become more efficacious, safer and more satisfying from the patient’s perspective. Bictegravir (BIC) is the...

IL-17A-Blockade bei mittelschwerer bis schwerer Plaque-Psoriasis

IL-17A-Blockade bei mittelschwerer bis schwerer Plaque-Psoriasis

Die Blockade von Interleukin (IL)-17A hat sich als Erfolgsmodell bei der Behandlung der mittelschweren bis schweren Plaque-Psoriasis etabliert. Für Secukinumab (Cosentyx®) liegen mittlerweile Daten...

Rosacea papulopustulosa

Rosacea papulopustulosa

Die chronische Gesichtsdermatose Rosacea ist für Patienten sehr belastend und kann mit erheblichen psychosozialen Beeinträchtigungen verbunden sein, wie die Online-Befragung BURDEN „Rosacea:...

Beyond an undetectable HIV viral load: an update for nurses and pharmacists

Beyond an undetectable HIV viral load: an update for nurses and pharmacists

Fiona Marple-Clark,a Alison Bell,b Hamish Bowden,c David Crawford,d Vickie Knight,e Samantha Libertino,f Don E Smithc,g...

Essential Knowledge Briefing: The Biotics Family in Early Life

THE BIOTICS FAMILY IN EARLY LIFE is the fourth book in an educational series on nutrition in early life. The first edition was launched in 2019, and now the 2nd edition with updated references and...

Zielgerichtete Therapie beim fortgeschrittenen BRAF-mutierten Melanom

Zielgerichtete Therapie beim fortgeschrittenen BRAF-mutierten Melanom

Im vergangenen Herbst wurde das Therapiespektrum beim nicht-resezierbaren oder metastasierten Melanom mit BRAFV600-Mutation durch die Kombination aus Encorafenib plus Binimetinib erweitert. So gibt...

1 … 11 12 13 14 15 … 38

Search Issues

RSS Feeds

  • All issues

Specialties

Click below to filter the KOM articles by specialty...

  • Allergy & Immunology
  • Cardiology
  • Conference
  • Critical Care
  • Dentistry
  • Dermatology
  • Diabetes & Endocrinology
  • Gastroenterology
  • General Medicine
  • Haematology
  • Hepatology
  • Infectious Diseases
  • Metabolic Disorders
  • Neurology
  • Nursing
  • Obstetrics & Gynaecology
  • Oncology
  • Paediatrics
  • Psychiatry
  • Rheumatology
  • Surgery Insights
  • Urology

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Share

Copyright © 2000-2026 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa